Slowing the Progression of Diabetic Kidney Disease
Cells · 2023
DOI: 10.3390/cells12151975 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2023. Verfasst von Olivia Blazek und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, American Heart Association Comprehensive Hypertension Center, The University of Chicago Medicine, Chicago, IL 60637, USA. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Diabetes is the most frequent cause of kidney disease that progresses to end-stage renal disease worldwide, and diabetic kidney disease is significantly related to unfavorable cardiovascular outcomes. Since the 1990s, specific therapies have emerged and been approved to slow the progression of diabetic kidney disease, namely, renin–angiotensin–aldosterone system blockers (including angiotensin-converting enzyme inhibitors (ACEi) angiotensin receptor blockers (ARBs), the non-steroidal mineralocorticoid receptor antagonist (NS-MRA), finerenone, and sodium–glucose cotransporter-2 (SGLT2) inhibitors). Mechanistically, these different classes of agents bring different anti-inflammatory, anti-fibrotic, and complementary hemodynamic effects to patients with diabetic kidney disease such that they have additive benefits on slowing disease progression. Within the coming year, there will be data on renal outcomes using the glucagon-like peptide-1 receptor agonist, semaglutide. All the aforementioned medications have also been shown to improve cardiovascular outcomes. Thus, all three classes (maximally dosed ACEi or ARB, low-dose SGLT-2 inhibitors, and the NS-MRA, finerenone) form the “pillars of therapy” such that, when used together, they maximally slow diabetic kidney disease progression. Ongoing studies aim to expand these pillars with additional medications to potentially normalize the decline in kidney function and reduce associated cardiovascular mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, American Heart Association Comprehensive Hypertension Center, The University of Chicago Medicine, Chicago, IL 60637, USA.
ORCID-Profile: George L Bakris
Zitieren
APA
Blazek, O., & Bakris, G. L. (2023). Slowing the Progression of Diabetic Kidney Disease. Cells. https://doi.org/10.3390/cells12151975
Vancouver
Blazek O, Bakris GL. Slowing the Progression of Diabetic Kidney Disease. Cells. 2023. doi:10.3390/cells12151975
BibTeX
@article{Blazek2023,
author = {Blazek, Olivia and Bakris, George L},
title = {Slowing the Progression of Diabetic Kidney Disease},
journal = {Cells},
year = {2023},
doi = {10.3390/cells12151975}
}
EUVIMED